STUDY00015328: Sepsis Endotypes

Enrolling by invitation

Conditions studied: Sepsis

In brief

Determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. We hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.

Key facts

Study ID

NCT03146546

Run by

Milton S. Hershey Medical Center

People needed

200

Starts

2020-08-06

Expected to finish

2026-06-30

Last updated by the study team

2025-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (age ≥ 18 )
• gender: male or female
• Cognitively intact or impaired patients, given that sepsis may cause a certain degree of cognitive dysfunction in patients. All patients in the control group (no sepsis) will be cognitively intact
• Clinical suspicion for sepsis (except for control/comparison group for whom infection is NOT a current concern)

You may not qualify if…

• Patients with hematologic malignancies
• Pregnant women
• Patient/surrogate is not fluent in English and no translation services are available
• Long-term immunosuppressive therapy
• Prisoner

Where it is running

• Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.